Journal of Hepatology
Volume 49, Issue 4 , Pages 613-624 , October 2008

Hepatitis C virus and kidney disease

  • Paul Martin

      Affiliations

    • Center for Liver Diseases, Miller School of Medicine, Department of Medicine, University of Miami, 1500 N.W. 12th Avenue, Suite 1101-E, Miami, FL 33136, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 (305) 547 2147; fax: +1 (305) 547 3877.
    • ,
  • Fabrizio Fabrizi

      Affiliations

    • Center for Liver Diseases, Miller School of Medicine, Department of Medicine, University of Miami, 1500 N.W. 12th Avenue, Suite 1101-E, Miami, FL 33136, USA
    • Division of Nephrology and Dialysis, Maggiore Hospital, IRCCS Foundation, Milano, Italy

References 

  1. Finelli L, Miller JT, Tokars JI, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61
  2. Fissell RB, Bragg-Gresham JI, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOOPS. Kidney Int. 2004;65:2335–2342
  3. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus infection in hemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904–909
  4. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3–10
  5. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH, et al. High prevalence of hepatitis C virus (HCV) DNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis. 1993;168:1343–1348
  6. Schneeberger PM, Keur I, van der Vliet W, van Hoek K, Boswijk H, van Loon AM, et al. Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol. 1998;36:1711–1715
  7. Okuda K, Hayashi J, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by hemodialysis. Lancet. 1999;347:909–910[letter]
  8. Rigopoulos E, Stefanidis I, Liaskos C, Zervou E, Rizos C, Mina P, et al. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol. 2005;34:81–85
  9. Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis. 2005;46:290–300
  10. Sanders-Saune K, Abravanel F, Nicot F, Peron JM, Alric L, Boineau J, et al. Detection and quantification of HCV RNA using real-time PCR after automated sample processing. J Med Virol. 2007;79:1821–1826
  11. Kaiser T, Damerow HC, Tenckhoff S, Finger A, Bottcher I, Hafer C, et al. Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J Med Virol. 2008;80:1195–1201
  12. Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant. 1999;14:2056–2059
  13. Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 2004;13:129–135
  14. Hmajed F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185–191
  15. Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 1992;38:44–48
  16. Pujol FH, Ponce IG, Lema MG, Capriles F, Devesa M, Sirti F, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol. 1996;34:1633–1636
  17. Chan TM, Lok ASF, Cheng IKP. Hepatitis C infection among dialysis patients: a comparison between patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1991;6:944–947
  18. Gilli P, Moretti M, Soffritti S, Marchi N, Malacarne F, Bedani PL, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs. 1990;13:737–741
  19. Fabrizi F, Lunghi G, Guarnori I, Raffaele L, Erba G, Pagano A, et al. Hepatitis C virus genotypes in chronic dialysis patients. Nephrol Dial Transplant. 1996;11:679–683
  20. Okuda KH, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusions among chronic haemodialysis patients. J Hepatol. 1995;23:28–31
  21. Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450–454
  22. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004–1010
  23. Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415–419
  24. Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infection at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752–760
  25. Arenas DJ, Paya S, Gonzalez C, Rivera F, Enriquez R. Isolation of HCV patients is efficient in reducing the annual incidence of HCV infection, but is it necessary?. Nephrol Dial Transplant. 1999;14:1337–1339
  26. Arenas MD, Sanchez-Paya J, Barril G, Garcia-Valdecasas J, Gorriz JL, Soriano A, et al. A multicentre survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20:1164–1171
  27. Simon N, Courouce‘ AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. 1994;46:504–511
  28. dos Santos JP, Loureiro A, Cendoroglo Neto V, Pereira BJG. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017–2022
  29. Jadoul M, Cornu C, van Ypersele de Strihou C and the Universitaires Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. Kidney Int. 1998;53:1022–1025
  30. Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron. 1995;70:301–306
  31. Kellerman S, Alter MJ. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology. 1999;29:291–293
  32. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR 2001; 50: 1–43.
  33. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron. 1998;80:428–433
  34. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896–1902
  35. Stehman-Breen C, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with HCV. Am J Kidney Dis. 1998;32:630–634
  36. Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis. 2006;48:629–637
  37. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive hemodialysis patients: a population-based study. Nephrol Dial Transplant. 2005;20:1662–1669
  38. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepatitis. 2007;14:697–703
  39. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–263
  40. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:1452–1461
  41. Cosio G, Sedmak DD, Henry ML, Al Haddad C, Falkenhain ME, Elkhammas EA, et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation. 1996;62:1054–1059
  42. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus infected renal allograft recipients. Transplantation. 1995;59:1676–1682
  43. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc. 2006;38:492–495
  44. Morales JM, Pascual-Capdevila J, Campistol JM, Fernandez-Zatarain G, Munoz MA, Andres A, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634–1639
  45. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract. 2005;100:c133–c139
  46. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Koff JM, Holtzmuller KC, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol. 2004;15:3166–3174
  47. Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C positive patients and renal transplant recipients. Am J Gastroenterol. 1999;94:159–163
  48. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation. 2000;69:1479–1483
  49. Sterling R, Sanyal A, Luketic V, Stravitz R, King A, Post A, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting liver transplantation. Am J Gastroenterol. 1999;94:3576–3581
  50. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44:1511–1517
  51. Kidney disease improving global outcomes (KDIGO): clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008;109:S1–S99.
  52. Pereira BJ, Milford E, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325:454–460
  53. Roth D, Zucker K, Cirocco R, Burke G, Olson L, Esquenazi V, et al. Transmission of hepatitis C virus by kidney transplantation: impact of perfusion techniques and course of viremia post transplant. Pediatr Nephrol. 1995;9:S29–S34
  54. Zucker K, Cirocco R, Roth D, Olson H, Burke GU, Nery J, et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation. 1994;57:832–840
  55. Vosnides G. Hepatitis C in renal transplantation. Kidney Int. 1997;52:843–861
  56. Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, et al. Transplantation of kidneys from donors with hepatitis C antibody to recipients with pre-transplantation anti-HCV. Kidney Int. 1995;47:236–240
  57. Ali MK, Light JA, Baryte DY, Sasaki TM, Currier CB, Grandas O, et al. Donor hepatitis virus status does not adversely short-term outcomes in HCV positive recipients in renal transplantation. Transplantation. 1998;66:1694–1697
  58. Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Abbott KC. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13:2974–2982
  59. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4:2032–2037
  60. Widell A, Mansson S, Persson NH, Thysell H, Hemodson S, Blohme I. Hepatitis C superinfection in hepatitis C virus -infected patients transplanted with an HCV-infected kidney. Transplantation. 1995;60:642–647
  61. Schussler T, Staffeld-Coit C, Eason J, Nair S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am J Transplant. 2004;4:1375–1378
  62. Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJG. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1999;56:700–706
  63. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 1995;47:1412–1418
  64. Koenig P, Vogel W, Umlauft F, Weyer K, Prommegger R, Lhotta K, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 1994;45:1507–1509
  65. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano T, Casanova A, Perez JL, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 2001;96:1170–1177
  66. Fernandez JL, Rendo P, del Pino N. Nephrologists group for the study of HCV infection and Viola L. A double-blind controlled trial of recombinant interferon-alpha2b in hemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepat. 1997;4:113–119
  67. Ozdemir FN, Aklcay A, Sezer S, Boyacioglu S, Ozdemir BH, Arat Z, et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail. 2004;26:583–588
  68. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-α therapy. J Infect Dis. 1997;176:1614–1617
  69. Campistol JM, Esforzado N, Martinez J, Rosello E, Veciana L, Modol J, et al. Efficacy and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Nephrol Dial Transplant. 1999;14:2704–2709
  70. Sporea I, Golea O, Ursu C, Totolici C, Popescu A, Sirli R, et al. Effect of alpha 2b interferon treatment in haemodialysis patients with chronic hepatitis C. Rom J Gastroenterol. 2001;4:285–288
  71. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, et al. Virological and histological responses to one-year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron. 2001;88:120–126
  72. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, et al. The tolerance and efficacy of interferon-alpha in hemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16:1017–1023
  73. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol. 2001;21:435–440
  74. Grgurevic I, Vince A, Buljevac M, Banic M, Jeren-Strujic B, Kes P, et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract. 2006;103:c8–c11
  75. Yildirim B, Durak H, Ozaras R, Canbakan B, Ozkan P, Ozbay G, et al. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment. Scand J Gastroenterol. 2006;41:1235–1241
  76. Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Transplant. 2006;17:338–343
  77. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 2006;26:305–310
  78. Rivera M, Gentil MA, Sayago M, Gonzalez-Roncero F, Trigo C, Algarra G, et al. Treatment of hepatitis C with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc. 2005;37:1424–1425
  79. Russo MW, Goldsweig C, Iacobson M, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003;98:1610–1615
  80. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15:79–88
  81. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena ?. Am J Kidney Dis. 2003;42:143–150
  82. Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyakee S, Sakai T, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron. 1998;80:51–56
  83. Rostaing L, Chatelut E, Payen JL, Thalamas C, Ton-That H, Pascal JP, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol. 1998;9:2344–2348
  84. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107–112
  85. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Consensus interferon study group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology. 1999;30:787–793
  86. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, et al. Safety of interferon and ribavirin therapy in hemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 2001;16:193–195
  87. Bruchfeld A, Stahle L, Andersson J, Schvarz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection- a pilot study. J Viral Hepat. 2001;8:287–292
  88. Mousa DH, Abdalla AH, Al-Shoail A, Al-Sulaiman H, Al-Hawas FA, Al-Khader A. Alpha interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831–1834
  89. Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40KD) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology. 2000;32:370A
  90. Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F, Selgas R, Carreno V. Pegylated interferon-alpha2a kinetics during experimental hemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther. 2004;20:37–44
  91. Gupta SK, Pittenger Al, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-α2b in patients with chronic renal dysfunction. J Clin Pharmacol. 2002;42:1109–1115
  92. Lamb MW, Marks IM, Modi MW, Preston RA, Pappas SC. Peginterferon alfa-2a (40KD) (Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology. 2001;34:326A
  93. Covic A, Maftei ID, Mardare NGI, Ionita-Radu F, Totolici C, Tuta L, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrology. 2006;19:794–801
  94. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc. 2003;35:1478–1479
  95. Annichiarico BE, Siciliano M. Pegylated interferon alpha2b monotherapy for HD patients with chronic HCV. Aliment Pharmacol Ther. 2004;20:123–127
  96. Teta D, Landtwing Luscher B, Gonvers J, Francioli P, Phan O, et al. Pegylated interferon for the treatment of hepatitis C virus in hemodialysis patients. Nephrol Dial Transplant. 2005;20:991–993
  97. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006;21:437–443
  98. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, et al. Pegylated interferon alpha2a treatment for chronic hepatitis C in patients on chronic hemodialysis. World J Gastroenterol. 2006;16:4191–4194
  99. Casanovas-Taltavull T, Baliellas C, Llobet M, Cruzado JM, Castellote J, Casanova A, et al. Preliminary results of treatment with pegylated interferon alpha 2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc. 2007;39:2125–2127
  100. Chan TM, Ho SKN, Tang CSO, Tse KC, Lam MF, Lai KN, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology. 2007;12:11–17
  101. Li CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alfa-2a versus standard interferon alfa-2a for treatment-naı¨ve dialysis patients with chronic hepatitis C: a randomized study. Gut. 2008;57:525–530
  102. Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol. 2008;14:255–259
  103. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in hemodialysed patients. J Viral Hepat. 2006;13:316–321
  104. Rendina M, Castellaneta NM, Castellaneta A, Losito A, Schena A, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alpha2a (40kDA) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:764–768
  105. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, et al. Pegylated interferon alfa-2a (40kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721–725
  106. Carriero D, Fabrizi F, Uriel A, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated-interferon and low dose ribavirin. Int J Artif Organs. 2008;31:295–302
  107. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426–1431
  108. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Ho Y, et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha 2b and ribavirin. J Hepatol. 2003;39:875–878
  109. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen LH, Lee WC, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation. 2004;77:1894–1905
  110. Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T, et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2007;12:22–27
  111. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006;24:1413–1422
  112. Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol. 2004;30:110–114
  113. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, et al. Histopathological efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation. 2004;78:853–857
  114. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis. 2003;42:184–192
  115. Calanca LN, Fehr T, Jochum W, Fischer-Vetter J, Mulhaupt B, Wutrich RP, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol. 2007;39:54–58
  116. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, et al. Evidence that clearance of hepatitis C virus RNA after interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092–2098
  117. Bunnapradist S, Fabrizi F, Vierling J, Martin P, Moudgil A, Kamil E, et al. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs. 2002;25:1189–1193
  118. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV RNA clearance. Am J Transplant. 2003;3:357–360
  119. Gursoy M, Guvener N, Koksal R, Karavelioglu D, Baysal C, Ozdemir N, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc. 2006;32:561–562
  120. Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J Gastroenterol Hepatol. 1998;13:62–67
  121. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol. 2002;58:143–150
  122. Suleymanlar I, Sezer T, Isitan F, Yakupoglu G, Suleymanlar G. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron. 1998;79:353–354letter
  123. Gursoy M, Gur G, Arsian H, Ozdemir N, Boycioglu S. Interferon therapy in hemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat. 2001;8:70–77
  124. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-α. Blood Purif. 2004;22:344–350
  125. Rocha S, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol. 2007;19:119–123
  126. Engel M, Malta F, Gomes M, Mello I, Pinho J, Ono-Nita S, et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health. 2007;7:50–55
  127. Al-Harbi A, Malik GH, Subaity Y, Mansy H, Abutaleh N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transplant. 2005;16:293–297
  128. Griveas I, Germanidis G, Morice Y, Perelson AS, Pawlotsky JM, Papadopoulou D. Acute hepatitis C in patients receiving hemodialysis. Ren Fail. 2007;29:731–736
  129. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–1276
  130. Fabrizi F, Martin P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opinion Organ Transplant. 2006;11:583–588
  131. Bruchfeld A, Lindahl K, Stahle L, Sodeberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18:1573–1580
  132. Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int. 2003;63:2236–2241
  133. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis. 2001;38:E35–E41
  134. Garini G, Allegri L, Iannuzzella F, Vaglio A, Buzio C. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed. 2007;78:51–59
  135. Saadoun P, Resche-Rigon M, Thibault V, Piette KC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritism Rheum. 2006;54:3696–3706
  136. Fabrizi F, Bruchfeld A, Mangano S, Dixit V, Messa P, Martin P. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs. 2007;30:212–219
  137. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994;46:1700–1704
  138. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330:751–756
  139. Komatsuda A, Imai H, Wakui H, Ohtani H, Kodama T, Oyama Y, et al. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Intern Med. 1996;35:529–533
  140. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, et al. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Digest Liver Dis. 2000;32:708–715
  141. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine. 2002;81:398–409
  142. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinaemic membranoproliferative glomerulonephritis. Am J Kidney Dis. 2004;43:617–623
  143. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004;19:3054–3061
  144. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in absence of steroids. Rheumatology. 2006;45:842–846
  145. Cohen H, Green S, Jones S, Amos N, William BD. Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinemia. Rheumatology. 2007;46:366–367

☆ PM has received grant support and honoraria from Roche Pharmaceuticals. He is a consultant for Roche. However, the authors declare that they did not receive any funding from any source to carry out this study.

PII: S0168-8278(08)00380-2

doi: 10.1016/j.jhep.2008.06.003

Journal of Hepatology
Volume 49, Issue 4 , Pages 613-624 , October 2008

Article Tools